Nature microbiology
Higher stability of novel live-attenuated oral poliovirus type 2 (nOPV2) despite the emergence of a neurovirulent double recombinant strain in Uganda.
Phionah Tushabe, Manasi Majumdar, Sarah Carlyle, Lester Shulman, Alfred Ssekagiri, Marie-Line Joffret, Dimitra Klapsa, Jeroen Cremer, Kafayat O Arowolo, Erika Bujaki, Henry Bukenya, EPI Laboratory team, Mary Bridget Nanteza, Irene Turyahabwe, Prossy Namuwulya
Published: 202610.1038/s41564-025-02219-w
Abstract
The novel oral poliovirus vaccine type 2 (nOPV2) was developed to reduce the risk of circulating vaccine-derived poliovirus outbreaks by incorporating genetic modifications to enhance genetic stability and reduce reversion to virulence while retainin…
Preview only. Read the full abstract at the source